WCM Investment Management Portfolio holdings
AUM
$43.8B
This Quarter Return
+11.39%
1 Year Return
+46.92%
3 Year Return
+145.55%
5 Year Return
+234.7%
10 Year Return
+793.48%
AUM
$39.4B
AUM Growth
+$39.4B
(+7.8%)
Cap. Flow
+$1.73B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
60.47%
Holding
212
New
22
Increased
129
Reduced
29
Closed
16
Top Buys
| 1 |
EPAM Systems
EPAM
|
$1.45B |
| 2 |
Entegris
ENTG
|
$309M |
| 3 |
Stryker
SYK
|
$148M |
| 4 |
Thermo Fisher Scientific
TMO
|
$143M |
| 5 |
Sherwin-Williams
SHW
|
$143M |
Top Sells
| 1 |
TSMC
TSM
|
$735M |
| 2 |
ASML
ASML
|
$610M |
| 3 |
Accenture
ACN
|
$542M |
| 4 |
HDFC Bank
HDB
|
$498M |
| 5 |
Smith & Nephew
SNN
|
$318M |
Sector Composition
| 1 | Technology | 35.58% |
| 2 | Healthcare | 23.05% |
| 3 | Consumer Discretionary | 15.14% |
| 4 | Financials | 10.85% |
| 5 | Industrials | 10.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Tandem Diabetes Care
TNDM
$834M
| $10M | 0.03% |
102,626
+32,475
| +46% | +$3.16M |
|
127
APi Group
APG
$14.4B
| $9.24M | 0.02% |
+442,243
| New | +$9.24M |
|
128
CryoPort
CYRX
$426M
| $8.95M | 0.02% |
141,816
+7,420
| +6% | +$468K |
|
129
Maximus
MMS
$4.99B
| $8.13M | 0.02% |
92,457
+3,587
| +4% | +$316K |
|
130
Fate Therapeutics
FATE
$115M
| $8.08M | 0.02% |
93,120
+3,696
| +4% | +$321K |
|
|
CCF
131
DELISTED
Chase Corporation
CCF
| $8.03M | 0.02% |
78,248
+4,736
| +6% | +$486K |
|
|
BHVN
132
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $7.98M | 0.02% |
82,213
+3,271
| +4% | +$318K |
|
|
NSTG
133
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.87M | 0.02% |
121,397
+28,525
| +31% | +$1.85M |
|
134
Caesars Entertainment
CZR
$5.18B
| $7.52M | 0.02% |
72,462
-114,723
| -61% | -$11.9M |
|
135
Arrowhead Research
ARWR
$3.84B
| $7.24M | 0.02% |
87,432
+3,383
| +4% | +$280K |
|
136
Ultragenyx Pharmaceutical
RARE
$3.04B
| $6.95M | 0.02% |
72,906
+2,841
| +4% | +$271K |
|
137
Elastic
ESTC
$9.17B
| $6.22M | 0.02% |
42,639
+38,151
| +850% | +$5.56M |
|
138
Halozyme
HALO
$8.75B
| $6.14M | 0.02% |
135,148
+5,225
| +4% | +$237K |
|
139
Axsome Therapeutics
AXSM
$6.09B
| $4.97M | 0.01% |
73,598
+2,934
| +4% | +$198K |
|
140
Insmed
INSM
$30.3B
| $4.54M | 0.01% |
159,499
+6,350
| +4% | +$181K |
|
141
Rocket Pharmaceuticals
RCKT
$358M
| $4.29M | 0.01% |
96,801
+3,811
| +4% | +$169K |
|
|
TPTX
142
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $4.24M | 0.01% |
54,315
+2,084
| +4% | +$163K |
|
143
BridgeBio Pharma
BBIO
$9.91B
| $3.96M | 0.01% |
65,022
-40,406
| -38% | -$2.46M |
|
144
Ligand Pharmaceuticals
LGND
$3.25B
| $3.93M | 0.01% |
29,921
+1,095
| +4% | +$144K |
|
145
Iovance Biotherapeutics
IOVA
$800M
| $3.93M | 0.01% |
150,839
+83,694
| +125% | +$2.18M |
|
|
RETA
146
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.76M | 0.01% |
26,576
-14,383
| -35% | -$2.04M |
|
147
Azenta
AZTA
$1.35B
| $3.69M | 0.01% |
+38,762
| New | +$3.69M |
|
148
Amazon
AMZN
$2.41T
| $3.68M | 0.01% |
1,069
| – | – |
|
149
Phathom Pharmaceuticals
PHAT
$843M
| $3.52M | 0.01% |
+103,987
| New | +$3.52M |
|
150
NetEase
NTES
$85.4B
| $3.32M | 0.01% |
28,784
+25,870
| +888% | +$2.98M |
|